

## PRODUCT INFORMATION

<b>Clone ID</b>	DMC680
<b>Target</b>	CXCR4
<b>Synonyms</b>	CD184; D2S201E; FB22; HM89; HSY3RR; LAP-3; LAP3; LCR1; LESTR; NPY3R; NPYR; NPYRL; NPY3R; WHIM; WHIMS
<b>Host Species</b>	Rabbit
<b>Description</b>	PE-conjugated Anti-CXCR4 antibody(DMC680), IgG1 Chimeric mAb
<b>Delivery</b>	Under Development
<b>Uniprot ID</b>	P61073; A0A0U3FJG0; A0A0U3GXA9
<b>IgG type</b>	Rabbit/Human Fc chimeric IgG1
<b>Clonality</b>	Monoclonal
<b>Reactivity</b>	Human
<b>Applications</b>	Flow Cyt
<b>Recommended Dilutions</b>	Flow Cyt 1:100
<b>Purification</b>	Purified from cell culture supernatant by affinity chromatography
<b>Formulation &amp; Reconstitution</b>	Liquid PBS with 0.05% Proclin300, 1% BSA
<b>Storage&amp;Shipping</b>	Store at 2°C-8°C for 6 months
<b>Background</b>	This gene encodes a CXC chemokine receptor specific for stromal cell-derived factor-1. The protein has 7 transmembrane regions and is located on the cell surface. It acts with the CD4 protein to support HIV entry into cells and is also highly expressed in breast cancer cells. Mutations in this gene have been associated with WHIM (warts; hypogammaglobulinemia; infections; and myelokathexis) syndrome. Alternate transcriptional splice variants; encoding different isoforms; have been characterized. [provided by RefSeq; Jul 2008]
<b>Usage</b>	Research use only
<b>Conjugate</b>	PE-conjugated
<b>DIMA Disclaimer</b>	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

